PHARMAC has no cost-effectiveness threshold

New Zealand Medical Journal

Volumn 125, Issue 1350, 2012, Pages

  Metcalfe, Scott ^a   Rodgers, Alexander ^a   Werner, Rachel ^a   Schousboe, Carsten ^a  

^a Pharmaceutical Management Agency   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUSTRY; FUNDING; HUMAN; INVESTMENT; QUALITY ADJUSTED LIFE YEAR;

EID: 84857508878     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. O'Keeffe KM, Gander PH, Scott WG, Scott HM. Insomnia treatment in New Zealand. N Z J Med 2012;125(1349):U5051. http://journal.nzma.org.nz/journal/125-1349/5051/
2. PHARMAC. Operating policies and procedures of the Pharmaceutical Management Agency ("PHARMAC"), Third Edition, January 2006. http://www.pharmac.govt.nz/2005/12/22/231205.pdf
3. Metcalfe S, Grocott R. Comments on Simoens, S. Health economic assessment: a methodological primer. Int. J. Environ. Res. Public Health 2009, 6,2950-2966-New Zealand in fact has no cost-effectiveness threshold. Int J Environ Res Public Health. 2010 Apr;7(4):1831-4. http://www.mdpi.com/1660-4601/7/4/1831/
4. Grocott R. Applying Programme Budgeting Marginal Analysis in the health sector: 12 years of experience. Exp Rev Pharmacoecon 2009;9:181-7 http://www.expertreviews.com/doi/abs/10.1586/erp.09.2
5. Prescription for Pharmacoeconomic Analysis: methods for cost-utility analysis, Version 2. PHARMAC: Wellington, New Zealand, 2007. http://www.pharmac.govt.nz/2007/06/19/PFPAFinal.pdf
6. Data derived from PHARMAC's Annual Reports to Parliament at http://www.pharmac.govt.nz/AnnualReport.
7. PHARMAC. Operating policies and procedures of the Pharmaceutical Management Agency ("PHARMAC"), Third Edition, January 2006. http://www.pharmac.govt.nz/2005/12/22/231205.pdf
8. Metcalfe S, Grocott R. Comments on Simoens, S. Health economic assessment: a methodological primer. Int. J. Environ. Res. Public Health 2009, 6,2950-2966 - New Zealand in fact has no cost-effectiveness threshold. Int J Environ Res Public Health. 2010 Apr;7(4):1831-4. http://www.mdpi.com/1660-4601/7/4/1831/
9. Grocott R. Applying Programme Budgeting Marginal Analysis in the health sector: 12 years of experience. Exp Rev Pharmacoecon 2009;9:181-7 http://www.expertreviews.com/doi/abs/10.1586/erp.09.2
10. Craig BA, Black MA. Incremental cost-effectiveness ratio and incremental net-health benefit: two sides of the same coin. Expert Rev Pharmacoecon Outcomes Res. 2001 Oct;1(1):37-46. http://www.expert-reviews.com/doi/pdf/10.1586/14737167.1.1.37
11. Zethraeus N, Johannesson M, Jönsson B, Löthgren M, Tambour M. Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies. Pharmacoeconomics. 2003;21(1):39-48. http://adisonline.com/pharmacoeconomics/Fulltext/2003/21010/Advantages_of_Using_the_Net_Benefit_Approach_for.3.aspx